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Background: Trifunctional bispecific antibodies (trAb) are a special class of bispecific molecules recruiting and
activating T cells and accessory immune cells simultaneously at the targeted tumor. The new trAb Ektomab that
targets the melanoma-associated ganglioside antigen GD2 and the signaling molecule human CD3 (hCD3) on T
cells demonstrated potent T-cell activation and tumor cell destruction in vitro. However, the relatively low affinity
for the GD2 antigen raised the question of its therapeutic capability. To further evaluate its efficacy in vivo it was
necessary to establish a mouse model.
Methods: We generated the surrogate trAb Surek, which possesses the identical anti-GD2 binding arm as Ektomab,
but targets mouse CD3 (mCD3) instead of hCD3, and evaluated its chemical and functional quality as a therapeutic
antibody homologue. The therapeutic and immunizing potential of Surek was investigated using B78-D14, a B16
melanoma transfected with GD2 and GD3 synthases and showing strong GD2 surface expression. The induction of
tumor-associated and autoreactive antibodies was evaluated.
Results: Despite its low affinity of approximately 107 M-1 for GD2, Surek exerted efficient tumor cell destruction
in vitro at an EC50 of 70ng/ml [0.47nM]. Furthermore, Surek showed strong therapeutic efficacy in a dose-dependent
manner and is superior to the parental GD2 mono-specific antibody, while the use of a control trAb with irrelevant
target specificity had no effect. The therapeutic activity of Surek was strictly dependent on CD4+ and CD8+ T cells,
and cured mice developed a long-term memory response against a second challenge even with GD2-negative B16
melanoma cells. Moreover, tumor protection was associated with humoral immune responses dominated by IgG2a
and IgG3 tumor-reactive antibodies indicating a Th1-biased immune response. Autoreactive antibodies against the
GD2 target antigen were not induced.
Conclusion: Our data suggest that Surek revealed strong tumor elimination and anti-tumor immunization
capabilities. The results warrant further clinical development of the human therapeutic equivalent antibody
Ektomab.
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The tumor-associated ganglioside GD2 is an attractive
target for immunotherapy. While its expression in nor-
mal tissue is restricted to the central nervous system
and peripheral nerves [1,2] it is strongly detectable on
neuroblastoma (NB) and on most melanoma lesions
[3,4]. Additionally, it is found on sarcoma, glioma and in
approximately 50%-100% of small cell lung cancers
(SCLC) where it is associated with enhanced cell prolif-
eration and invasive activity [5-7]. Due to its distribution
pattern, GD2 has been chosen as a target for monoclo-
nal antibody therapy. Early clinical trials indicated certain
efficacy especially in the treatment of NB [8]. Recently,
the GD2-specific chimeric antibody ch14.18 in combin-
ation with IL-2 and GM-CSF demonstrated improved
overall survival in high risk NB patients as compared to
standard therapy (isotretionin) alone [9]. Undoubtedly,
this study validates GD2-targeted immunotherapy for
NB patients without bulky disease. However, treatment
of other solid GD2-positive tumors like melanoma has
shown limited clinical success so far [10,11]. A promising
new approach might be provided by genetically engi-
neered T cells expressing GD2-specific chimeric antigen
receptors, which demonstrated anti-melanoma activity in
a xenograft model [12].
Alternatively, GD2-targeting bispecific molecules may
be applied to recruit T cells to the tumor thereby avoid-
ing T-cell manipulation ex vivo. Trifunctional bispecific
antibodies (trAb) represent a new class of T cell-recruiting
immunotherapeutics with enhanced effector functions.
They consist of a binding arm directed against a tumor-
associated antigen (TAA), a second binding arm specific
for CD3 on T cells and a chimeric mouse IgG2a x rat
IgG2b Fc region that shows preferential binding of acti-
vating Fcγ receptors (FcγR) expressed on monocytes,
macrophages, dendritic and natural killer cells [13,14].
TrAb induce a concerted and highly efficient attack
against tumor cells by redirecting different types of im-
mune effector cells as shown in vitro [15-17] and in vivo
[18-20]. In 2009, with catumaxomab (anti-EpCAM x
anti-CD3), the first bispecific antibody worldwide was
approved in the European Union for the treatment of
malignant ascites in patients with EpCAM-positive tu-
mors [21]. This motivated the development of further
trAb designed for other cancer entities such as melan-
oma. A GD2-specific trAb (TRBs07/Ektomab) demon-
strated significant cytotoxic potential against melanoma
cells in vitro [22]. However, the relatively low GD2 affin-
ity of this trAb was a matter of concern and raised the
question of its in vivo efficacy. Therefore, we developed
the surrogate trAb Surek that consists of the identical
anti-GD2 binding arm but targets mouse instead of
human CD3. Thus, Surek can be used in experimental
tumor models using immune competent mice for thetreatment of GD2-positive malignant disease. Here, we
report on the characterization of this surrogate antibody
and on its effective in vivo application as a preclinical re-
search biologic.
Methods
Manufacture and quality control of Surek and control
antibodies
The trAb Surek (anti-GD2 x anti-mouse CD3), its paren-
tal control antibodies Me361 [23] (anti-GD2; mouse
IgG2a/kappa), 17A2 [24] (anti-mouse CD3; rat IgG2b/
kappa), and its therapeutic homologue Ektomab/TRBs07
[22] (anti-GD2 x anti-human CD3) and the control trAb
TRBs01 (anti-HER2/neu x anti-mouse CD3) were pro-
duced by quadroma or hybridoma cells according to the
TRION antibody platform technology as described [13].
For the manufacture, chemically defined protein-free
medium was used (Invitrogen, USA). Endotoxin con-
tent of purified antibody stock solutions was measured
by Limulus amebocyte lysate (LAL) gel clotting test
(Pyroquant Diagnostik, Germany). Monomer and ag-
gregate distribution was determined by size exclusion
(SE) – HPLC (HP 1100 system, Agilent, USA) using a
TSKgel G3000SWXL column (Tosoh Biosep, USA). For
reduced mass analysis and determination of the peak area
ratio of the antibody chains, Surek samples were dena-
tured by using 6M guanidine, reduced with dithiothreitol
and alkylated with iodacetamid. The samples were ana-
lyzed by means of RP-HPLC ESI-TOF-MS (Agilent 1200
online coupled with an Agilent 6220 ESI-TOF, CA, USA)
using a 250 mm x 2 mm Jupiter C5 column, packed with
5 μm particles, 300 Å pore size (Phenomenex, Torrance,
CA, USA). The raw mass spectra of the antibody chains
were converted using MassHunter software to calculate
the observed masses. The reversed phase chromatogram
with UV absorbance at 214 nm was used for the de-
termination of the peak area ratio. Bispecific binding ac-
tivity of Surek and Ektomab was evaluated by flow
cytometry with a FACSCalibur (Becton Dickinson, USA).
GD2-positive B78-D14 [25] and mouse CD3-positive
LBRM-33 (ATCC: TIB-155) cells served as targets. Cell-
bound trifunctional bispecific antibodies were either
detected by FITC-labelled anti-mouse IgG or anti-rat IgG
secondary antibodies (Dianova, Germany). The GD2-
specific control antibody 14G2a [26] was purchased from
Santa Cruz Biotechnology (CA, USA).
Antibody binding to GD2 and GD3
Relative binding affinity of Surek to the gangliosides
GD2 and GD3 was measured by ELISA. Briefly, ELISA
plates (high binding, Greiner bio-one, Germany) were
coated with 0.2 μg/well GD2 or GD3 (purified from
human brain, Biomol, Germany) in ethanol, dried and
blocked over night with SuperBlock blocking buffer
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Surek and control antibodies Me361, 14G2a and Ekto-
mab were added in PBS containing 4% bovine serum al-
bumin at the indicated concentrations. After one hour,
plates were washed and bound antibodies were detected
with a mixture of biotin-conjugated F(ab0)2 anti-mouse/
rat IgG specific detection antibodies (Jackson Immuno
Research, USA). Then, streptavidin β-galactosidase and
finally its corresponding substrate, chlorphenolred-β-D-
galactopyranosid (Roche Diagnostics, Germany), were
added, and the colorimetric reaction was measured at
570 nm by a VersaMax microplate reader (Molecular
Devices, USA). Sigmoidal binding curves were five par-
ameter fitted using GraphPad Prism software (version
5.02) and EC50 values were compared.
Cytotoxicity assay
Antibody-mediated cellular cytotoxicity was measured
by a colorimetric 2,3-bis[2-methoxy-4-nitro-5-sulfophe-
nyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT)-
based assay. Briefly, GD2-positive B78-D14 target cells
were coincubated with mouse effector cells in the pres-
ence of indicated antibody concentrations in 96-well
flat-bottom plates. The effector to target ratio was 50:1.
As effector cells we used spleen and lymph node cells of
naïve C57BL/6 mice after enriching T cells in one round
of B-lymphocyte panning with anti-IgG+M antibodies
(Dianova, Germany). Moreover, macrophages derived
from peritoneal lavage were added to increase the num-
ber of accessory immune cells. The effector cell pop-
ulation consisted of about 40% CD4+/CD3+ T-cells,
25% CD8+/CD3+ T cells, 10% CD11b+ macrophages/
monocytes, 5% CD3-/NK1.1+ NK cells, and 15% re-
maining CD3-/CD19+ B-cells as determined by flow cy-
tometry (data not shown). After three days, effector cells
were removed by washing. Adherent viable tumor cells
were stained with XTT cell proliferation kit II (Roche
Diagnostics, Germany). Absorbance was measured in a
Versamax microplate reader and % cell killing was calcu-
lated as follows: [(absorbance target cells - absorbance
sample)/(absorbance target cells – absorbance effector
cells)] x 100. Each sample was performed in quadrupli-
cates. Surek Kiling curves of mean values were fitted
using five parameter equation of GraphPad Prism soft-
ware (version 5.02).
Cells, mice and tumor models
The GD2-positive B78-D14 mouse melanoma cell line
was derived from GD2-negative B16 cells by transfection
with genes coding for the GD3 and GD2 synthases as
described [25]. The cell line was a kind gift of Prof. J. C.
Becker (Graz, Austria). Cells were cultivated in RPMI
1640 medium supplemented with 8.9% fetal calf serum,
2 mM L-glutamine, 1 mM sodium pyruvate, and 1 xnonessential amino acids. Additionally, 400 μg G418 and
500 μg Hygromycin B per ml were added to the B78-
D14 cell culture. Cells were extensively washed in PBS
before in vivo application.
C57BL/6J mice (Taconic, Denmark), 9 to 12 weeks of
age, were injected i.p. with 1–5 × 105 tumor cells fol-
lowed by Surek or Me361 control antibody treatment as
outlined. In depletion experiments, either CD8+ or CD4+
T cells were eliminated by injecting 0.5 mg of the cell-
depleting antibodies RmCD4 or RmCD8 on day −4 and
subsequently 0.1 mg on days 1 and 14. Long-term sur-
vivors of a primary tumor challenge were re-challenged
23 weeks later with 3 × 103 GD2-negative B16 wildtype
cells without any further treatment to assess anti-tumor
immunity. In all experiments tumor control groups re-
ceiving tumors cells only were performed. For adoptive
plasma transfer experiments 200 μl of immune or naïve
control plasma were ex vivo mixed together with 3 × 103
B16 tumor cells and i.p. administered into naïve mice.
Mice were killed after apparent i.p. tumor growth (ab-
dominal swelling) that was confirmed by dissection post
mortem. For the assessment of tumor-reactive antibodies,
blood samples were collected three weeks after Surek
therapy of the primary tumor challenge and two weeks
after tumor re-challenge. All animal experiments were in
accordance with relevant regulations and had been ap-
proved by the local authority.Detection of tumor-reactive antibodies
Antibodies against whole tumor cells were measured by
flow cytometry using either B78-D14 or B16-F0 as target
cells. Mouse plasma samples were incubated at a final
dilution of 1:30 with 2–4 × 105 tumor cells for 60 min at
2-8°C. After two washing rounds, cell-bound antibodies
were detected by a FITC-conjugated rat-anti-mouse IgG
(Dianova, Germany) or by subclass-specific goat anti-
mouse IgG1, IgG2a and IgG3 secondary detection anti-
bodies (Southern Biotechnology, USA). Mean fluores-
cence intensity (MFI) and % of positively stained cells
were determined with a FACSCalibur cytometer and corre-
sponding CellQuest analysis program (Becton Dickinson,
USA). Nonspecific (background) binding of secondary anti-
bodies alone was below 5%. GD2-specific antibodies were
quantified by ELISA. Therefore, mouse plasma samples
were two-fold serially diluted on GD2-coated >ELISA
plates and bound antibodies were detected by a mix-
ture of biotin-conjugated rat anti-mouse IgG1, 2a, 2b
and 3 specific antibodies (gift of E. Kremmer, Helmholtz-
Zentrum München, Germany). The GD2-binding anti-
body Me361 was used as a positive control. Antibody
titers were defined by the highest sample dilution with sig-
nificant signal above buffer background (mean background +
3 x SD).























































Figure 1 Binding of Surek and control antibodies. (A) Three
different production batches A, B and C of Surek were compared for
bispecific binding to either GD2 positive B78-D14 or to mouse CD3
expressing LBRM-33 cell lines by flow cytometry. In mean, binding
to mouse CD3 (EC50 = 0.16 μg/ml [1.07 nM]) was 23 times stronger
than binding to GD2 (EC50 = 3.6 μg/ml [24 nM]). (B) Binding curves
of the monoclonal antibodies Me361, 14G2a, Surek and Ektomab to
GD2 as measured by ELISA are displayed. Additionally, cross-reaction
of Surek with GD3 is included. The figure shows one representative
of three independent experiments. Mean calculated EC50 values
were 0.018 μg/ml [0.12 nM] (Me361), 0.073 μg/ml [0.49 nM] (14G2a),
4.8 μg/ml [32 nM] (Surek) and 3.1 μg/ml [20.7 nM] (Ektomab).
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Differences in anti-antibody titers were statistically ana-
lyzed by unpaired, two-tailed Students t-test. Survival
curves of mice were compared by log-rank test. P values
< 0.05 were considered statistically significant. GraphPad
Prism software version 5.02 (GraphPad Software) was
used for generation of survival curves, titer plots and
statistical calculations.
Results
Chemical and functional quality of the therapeutic
antibody homologue Surek
The trifunctional surrogate antibody Surek was manu-
factured according to the antibody platform technology
developed by TRION as described elsewhere [13]. Ana-
lysis of three production batches showed very low ag-
gregate content (< 1%) and acceptable low endotoxin
contamination of less than 102 EU/ml. Reversed phase
HPLC and mass spectrometric analysis confirmed the
presence of all four mouse and rat Ig heavy and light
chains in an almost ideally 1:1:1:1 proportion (not shown).
Moreover, comparable bispecific binding to GD2 and
mouse CD3 positive cell lines could be demonstrated
for all three batches by flow cytometry (Figure 1A).
Next, we investigated the specificity and affinity of
Surek for GD2 by ELISA. There was only weak cross
reactivity with the most related ganglioside structure
GD3 at therapeutically irrelevant high concentrations of
>100 μg/ml (Figure 1B). Since both antibodies contain
the identical anti-GD2 binding arm, Surek and its thera-
peutic equivalent Ektomab showed similar binding
curves, as expected. Moreover, relative binding affinity
for both monovalent antibodies was 40–70 times weaker
as compared to the bivalent GD2-specific mouse anti-
body 14G2a whose association constant for cell-bound
GD2 was determined with 1,5 × 108 M-1 [26]. Thus,
Surek and Ektomab represent antibodies for the GD2
antigen with an estimated association constant in the 107
M-1 range. Best binding results were obtained with par-
ental antibody Me361 which bound approximately 4
times stronger in comparison to 14G2a.
Finally, we characterized the functional activity of Surek
by measuring the cytotoxicity against GD2-positive B78-
D14 mouse melanoma cells in the presence of mouse
effector T and accessory immune cells. In Figure 2, three
independent experiments are summarized showing that
Surek mediated effective elimination of tumor cells with
a calculated mean EC50 of 70 ng/ml [0.47 nM]. In con-
trast, the parental anti-GD2 mouse antibody Me361 was
only effective at the highest used concentration of 10,000
ng/ml, probably acting through the mechanism of ADCC
as indicated previously [27]. The addition of the parental
anti-CD3 antibody 17A2 did not increase Me361 cyto-
toxic activity indicating that nonspecific T-cell activationdid not contribute to tumor cell destruction. This was
further confirmed with the control trAb TRBs01 that
cannot bind to the B78-D14 target cells and accordingly
revealed no cytotoxicity. Of note, tumor cell killing activ-
ity of bsF(ab0)2 fragments was strongly impaired empha-
sizing the importance of the Fc part of Surek for its
therapeutic efficacy (manuscript submitted).
Dose- and T cell-dependent therapeutic effect of Surek
in vivo
We tested the in vivo efficacy of Surek by monitoring
the inhibition of intraperitoneally (i.p.) growing B78-D14

























Figure 2 Surek-mediated killing of GD2-positive B78-D14
melanoma cells by mouse immune effector cells. Tumor cell
killing was measured by an XTT-based long-term cytotoxicity assay
using enriched T cells and peritoneal macrophages at an effector to
target ratio of 50:1. Surek antibody mediated efficient killing of
B78-D14 cells with a mean EC50 of 70 ng/ml [0.47 nM]. Anti-GD2
parental antibody Me361 was only effective at the highest tested
concentration of 10,000 ng/ml; the addition of the second parental
antibody 17A2 (anti-mouse CD3) did not improve killing activity, nor
had the control trAb TRBs01 (anti-HER2/neu x anti-mCD3) any effect.
The figure summarizes three independent experiments. Error bars
indicate SD.
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2 × 105 tumor cells and received three consecutive injec-
tions (i.p.) of Surek on days 2, 7 and 11 after tumor chal-
lenge. Three doses of 50 μg (high), 10 μg (middle) or 3
μg (low) per injection were given. Control animals
received tumor cells but no antibody. The corresponding
survival curves clearly demonstrate a dose-dependent
therapeutic effect of Surek. In both experiments, tumor
growth was completely impeded in all animals (100%) at
the highest dose of 50 μg (Figure 3A, B). Survival rates
of the low and middle dosing groups depended on the
number of initially applied tumor cells. Prolongation of
survival in comparison to the control groups, which
showed 14% and 11% survivors, respectively, was signifi-
cantly improved for all Surek treatment groups except
for the lowest dosing group of 3 μg in combination with
the high tumor cell burden.
Importantly, Surek significantly improved (p < 0.0001)
the therapeutic outcome in comparison to the parental
anti-GD2 monospecific antibody Me361. After applica-
tion of 5 × 105 tumor cells, the median survival time of
mice was increased from 43.5 days (control) to 52 days
by Me361 and further to 67 days by Surek (Figure 3C).
This suggests that the therapeutic activity of Surek
mainly results from T cells and that mono-specific anti-
body-mediated killing mechanisms like ADCC and CDC
as observed for anti-GD2 antibody 14G2a [28] play a
minor role. This assumption was confirmed by T-celldepletion experiments. In vivo depletion of CD8+ and of
CD4+ T cells, respectively, completely abrogated the
therapeutic effect of Surek indicating that both T cell
subpopulations are required (Figure 3D). Finally, Surek-
mediated tumor elimination was specific since the use of
the control trAb TRBs01 with unrelated target specificity
had no impact on the survival of the mice (Figure 3C).
Long-term anti-tumor immunization induced after Surek
therapy
Having shown that, in spite of its relatively low affinity,
Surek efficiently eradicates GD2-positive melanoma
cells in vivo, we addressed the question whether this
antibody is also capable of inducing long-lasting anti-
tumor immunization effects. Recently, tumor-protective
immunization has been observed with the high affinity
EpCAM-specific surrogate antibody BiLu [18,29]. There-
fore, we re-challenged long-term survivors 23 weeks
after Surek therapy with a lethal dose of B16F0 wild type
melanoma cells. In contrast to non-immunized control
animals, all of which developed tumors within 4 weeks,
50% of the immunized mice displayed tumor protection
and completely rejected a tumor challenge (Figure 4A,
p < 0.0001). When we analyzed plasma samples taken
14 days after tumor re-challenge for tumor-reactive an-
tibodies, we found a strong anti-B16F0 immune re-
sponse in the Surek pre-treated group (Figure 4B). IgG
subclass analyses indicated a Th1 response with domin-
ant IgG3 and IgG2a but low IgG1 titers (Table 1). Inter-
estingly, antibody responses were not directed against the
target antigen GD2 as evaluated by ELISA: Plasma sam-
ples collected 3 weeks after Surek treatment were negative
for GD2-specific antibodies (Figure 4C). On the other
hand, 5 of 9 mice treated with Surek showed a clear re-
sponse against whole B78-D14 tumor cells that was sig-
nificant in comparison to the control group (p = 0.024).
This demonstrates that Surek therapy induced tumor-
reactive antibodies but did not evoke autoimmune reac-
tions against the endogenous tumor-associated glycolipid
GD2. Finally, by performing adoptive plasma transfer
experiments we demonstrated that the tumor-reactive
antibodies themselves had only marginal if any inhibitory
effects on tumor growth. Median survival of immune
plasma versus naïve plasma treated mice was 25 versus
22 days (Figure 5).
Discussion
Bispecific antibodies (bsAb) are considered as a promis-
ing improvement of traditional monospecific antibodies
for instance because effector functions are enhanced and
the risk of drug resistance is reduced [30]. Among the
many different formats, trAb are most advanced with
catumaxomab being the first EMA-approved bsAb so far
[21]. Here, we present preclinical data of the new trAb
A B
C D
Figure 3 Therapeutic effectiveness of Surek. Survival of mice i.p. injected with different numbers of B78-D14 tumor cells followed by Surek
therapy was evaluated. Mice were administered with either 1 × 105 (A) or with 2 × 105 (B) B78-D14 cells and subsequently received three
injections of Surek antibody within 11 days, except for the tumor control. Three dosing groups of 3, 10 and 50 μg antibody were performed.
Each group comprised 9 mice. Asterisks indicate statistical significance in comparison to the control group according to the log rank test with p
values of < 0.05 (*), < 0.01 (**), and < 0.001 (***), respectively. (C) Superior therapeutic effect of Surek in comparison with the parental anti-GD2
antibody Me361 and the control trAb TRBs01 (anti-HER2/neu x anti-mCD3) was observed. Mice were challenged i.p. with 5 × 105 B78-D14 cells
and treated with three injections of either 50 μg Surek (n=15), 50 μg Me361 (n=16), or 50 μg TRBs01 (n=10) antibody, or left untreated (control,
n=10). Survival of mice treated with Surek was significantly prolonged in comparison to the Me361 and TRBs01 treatment groups (log-rank test, p
< 0.0001). (D) The therapeutic activity of Surek depends on the presence of T cells. Mice (n=6) were challenged i.p. with 1 × 105 B78-D14 cells on
day 0 and treated with 10 μg Surek on days 2 and 10 after tumor challenge. T cells were abrogated by injection of depletion antibodies RmCD4
and RmCD8 on days −4, 1 and 14.
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GD2 and mCD3 on T cells. A critical point of investiga-
tion was the relatively low affinity of the antibodies’
tumor binding arm (~107 M-1) recognizing a sugar epi-
tope. However, in spite of this fact, Surek showed thera-
peutic effectiveness in the treatment of the GD2-positive
B78-D14 melanoma model. The therapeutic outcome was
superior to the parental monospecific antibody treatment,
specific and dose-dependent with a cumulative dose of
150μg required to accomplish complete tumor rejection
(Figures 3A, B, C). In comparison with the high-affinity
EpCAM-specific surrogate antibody BiLu (~109 M-1),
which was evaluated in a similar melanoma model, the
required therapeutic dosage is about 15–30 times higher
[18,29]. This can be partially ascribed to the different af-
finities of the tumor binding arms. However, the finding
that Surek is capable of redirecting T-cell cytotoxicity at
all (EC50 = 70 ng/ml [0.47 nM]) may be explained by
multivalent binding of redirected T cells opsonized witha multitude of Surek antibody molecules. This hypothesis
implies a much higher affinity of the monovalent CD3
binding arm of Surek which was indeed confirmed by
comparative FACS binding studies (Figure 1A). Depletion
experiments further confirmed that the in vivo mode of
action of Surek is also strictly dependent on T cells.
Interestingly, both CD8+ as well as CD4+ T cells are es-
sential for therapeutic effectiveness (Figure 3D) suggest-
ing that CD4+ T helper cells contribute to the tumor
destruction either directly or indirectly e.g. by promoting
T-cell activation via cross-talk with accessory immune
cells.
A considerable concern of anti-GD2 antibodies is the
triggering of neurotoxicity [31]. Antibody binding to
GD2 expressed as a minor constituent in normal periph-
eral nerves causes severe pain requiring analgetic med-
ication [32-34]. Importantly, we did not observe any
apparent signs of neurotoxicity in mice after administra-
tion of Surek. Of note, the GD2 binding arm of the
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Figure 4 Survival of mice after tumor rechallenge and induced
humoral immune response. (A) Long-term survivors were
rechallenged (i.p.) with 3 × 103 B16-F0 cells 23 weeks after Surek
therapy. Six of 12 mice (50%) completely rejected the second tumor
challenge in contrast to non pre-treated control mice (n = 10;
log-rank test, p < 0.0001). Data of two independent experiments
were summarized. (B) The binding of individual mouse plasma
samples to B16 F0 cells was analyzed by FACS. Samples of long-term
survivors (Surek pre-treated) or non-pretreated mice (control) were
collected 14 days after tumor rechallenge with B16-F0 cells. The two
analyzed sample groups are significantly different (p < 0.0001).
(C) Induced tumor reactive antibodies are not directed against the
target antigen GD2. Mice were i.p. treated as indicated in Figure 3
with 1 × 105 B78-D14 tumor cells followed by 3 × 50 μg of Surek.
Control animals were either left untreated or received only tumor
cells. Three weeks after therapy, plasma samples were collected and
analyzed for anti-GD2 (left panel) and for anti-B78-D14 antibodies
(right panel). Only background anti-GD2 titers were detectable
whereas a significant reaction with B78-D14 cells was observed in
the group treated with tumor cells and Surek antibody as indicated
by the asterisk (p = 0.024).
Table 1 IgG subclass analysis of tumor-reactive
antibodies from long-term survivors
Sample Classification
IgG1 IgG2a IgG3
1 - + +++
2 - - +++
3 ++ - +
4 - - +
5 - - +++
6 - + ++
7 - + +++
8 + ++ +
9 + +++ +++
10 + +++ +++
11 + +++ +++
12 ++ +++ +++
Classification according to anti-B16-F0 staining: <5% = negative, 5-20% = +;
21-50% = ++;51-100% = +++.
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anti-hCD3) showed no cross- reactive binding to 32 dif-
ferent normal human tissues including peripheral nerves.
The only exception was cerebellum (unpublished data).
Thus, the relatively low affinity of Ektomab obviously
avoids its monospecific binding to healthy tissue and
seems to be advantageous in terms of circumventing
dose-limiting neurotoxicity. Moreover, the high specifi-
city of the parental antibody Me361, which provides theGD2-binding arm of Ektomab and Surek, prevents sig-
nificant cross-reactive binding with prominent gangli-
oside species like GM1 or GM3 [35]. We found that even
with the most similar ganglioside structure GD3, there
was only minimal cross-detection at high antibody con-
centrations of > 100 μg/ml (Figure 1B). Selecting ther-
apeutic mAbs with an appropriate affinity is often a
matter of debate that can only be answered in the clinic.
For instance, high-affinity EpCAM-specific mAbs were
shown to cause severe acute pancreatitis, whereas low-
affinity counterparts lacked sufficient effector func-
tions [36].
TrAb represent an attractive approach in cancer ther-
apy because they link innate and adaptive immunity [37].
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Figure 5 Adoptive transfer of immune plasma. The adoptive
transfer of 200 μl of immune plasma simultaneously administered i.
p. together with 3 × 103 B16 F0 cells had only a marginal if any
effect on tumor growth in comparison to the transfer of naïve
plasma: Median survival of mice (n = 7) was 25 versus 22 days (log-
rank test, p = 0.044). The inlet figure demonstrates that 90% of B16
F0 cells were stained positive by the mouse immune plasma. The
experiment was once repeated with similar results.
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trAb Surek and other trAb like BiLu [18,29] or catumax-
omab [38] are equally competent in inducing long-term
vaccination. Indeed, a proportion of 50% of Surek-treated
long-term survivors were resistant to a lethal second
tumor challenge without any further antibody injection
(Figure 4A). Anti-tumor immunization was associated
with the formation of tumor-reactive antibodies which,
however, only marginally contribute to tumor protection
as shown by plasma transfer experiments (Figure 5). In
fact, the measured humoral immune response which
was dominated by IgG2a and IgG3 isotypes indicates
an IL-12-mediated and Th1-associated T-cell immunity
[39,40]. Indeed, activation of dendritic and T cells was
observed by Eissler et al. 48h after in vivo application
of Surek accompanied by IL-12, IFN-γ and TNF release.
Moreover, protective tumor-specific T cells recognizing
melanoma-derived peptides like tyrosinase-related pro-
tein 2 (trp2) and gp100 were induced after immunization
of mice with irradiated B78-D14 tumor cells and intact
Surek antibody but not with the bsF(ab0)2 counterpart
lacking the Fc region [41]. Thus, Surek effectively elimi-
nates B78-D14 melanoma cells in vivo followed by the in-
duction of long-term anti-tumor immunization. Of note,
we did not detect autoreactive antibodies directed against
the target structure GD2 indicating that Surek therapy
does not break tolerance to self antigens. This is an im-
portant finding because ganglioside-directed autoimmune
reactions were shown to cause severe neurological dis-
orders in some patients [31].Immunotherapeutic approaches are especially attract-
ive for the treatment of immunogenic cancers like mel-
anoma. This is underscored by the recent approval of
the monoclonal antibody Ipilimumab [42], which blocks
the negative T-cell regulator CTLA-4 [43]. However, se-
vere autoimmune effects like hepatitis or enterocolitis
are frequently observed in the course of Ipilimumab
treatment. In contrast to nonspecific immune modula-
tors, trAb represent a targeted immunotherapeutic ap-
proach. They offer the advantage of redirecting and
activating T cells and antigen-presenting cells simultan-
eously at the tumor site and thus combining passive and
active immunization [37]. Hence, trAb may be especially
effective in the treatment of immunogenic melanoma.
Our data demonstrate that the trAb Surek, which targets
the melanoma-associated antigen GD2, effectively elimi-
nates melanoma cells accompanied by the generation of
an immunological memory. The typical characteristics of
targeted cell destruction and induced long-term immune
responses are observed for Surek. These results warrant
further clinical development of its therapeutic equivalent
Ektomab.
Conclusions
The mode of action and the efficacy of trifunctional bis-
pecific antibodies (trAb) binding with high affinity to
targeted tumor-associated surface proteins like EpCAM
or HER2/neu are well described. This was impressively
demonstrated with the first clinical approval of the trAb
catumaxomab (RemovabW) in 2009. Our results obtained
with Surek suggest that the concept of trAb for tumor
therapy can also be extended to trAb recognizing sugar
epitopes with low affinity. Surek revealed similar in vivo
efficacy and immunizing potency like the high-affinity
surrogate trAb BiLu although significant higher amounts
of antibody were required. Nonetheless, there may be a
therapeutic window with augmented tolerated dosages
for GD2-targeting trAb due to the high tumor specificity
of the expressed ganglioside. In the context of induced
neurotoxicity as observed for other GD2-specific mAbs
a low affinity trAb is likely to be more tolerable. In sum-
mary, our results warrant the further clinical develop-
ment of GD2-targeting trAb like e.g. Ektomab.
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